Aytu BioPharma, Inc. (AYTU)
2.00
+0.03
(+1.52%)
USD |
NASDAQ |
Oct 13, 16:00
2.00
0.00 (0.00%)
After-Hours: 20:00
Aytu BioPharma Enterprise Value : 12.93M for Oct. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 12, 2026 | 12.93M |
| October 09, 2026 | 13.52M |
| October 08, 2026 | 13.79M |
| October 07, 2026 | 13.79M |
| October 06, 2026 | 13.79M |
| October 05, 2026 | 13.68M |
| October 02, 2026 | 14.01M |
| October 01, 2026 | 14.22M |
| September 30, 2026 | 14.76M |
| September 29, 2026 | 15.40M |
| September 28, 2026 | 15.08M |
| September 25, 2026 | 16.26M |
| September 24, 2026 | 16.58M |
| September 23, 2026 | 16.26M |
| September 22, 2026 | 15.72M |
| September 21, 2026 | 14.60M |
| September 18, 2026 | 14.54M |
| September 17, 2026 | 13.25M |
| September 16, 2026 | 12.93M |
| September 15, 2026 | 13.15M |
| September 14, 2026 | 13.25M |
| September 11, 2026 | 13.15M |
| September 10, 2026 | 13.79M |
| September 09, 2026 | 14.54M |
| September 08, 2026 | 15.29M |
| Date | Value |
|---|---|
| September 04, 2026 | 15.51M |
| September 03, 2026 | 16.31M |
| September 02, 2026 | 16.26M |
| September 01, 2026 | 15.94M |
| August 31, 2026 | 16.37M |
| August 28, 2026 | 15.94M |
| August 27, 2026 | 15.83M |
| August 26, 2026 | 16.47M |
| August 25, 2026 | 17.01M |
| August 24, 2026 | 16.58M |
| August 21, 2026 | 17.22M |
| August 20, 2026 | 16.26M |
| August 19, 2026 | 17.12M |
| August 18, 2026 | 17.12M |
| August 17, 2026 | 17.12M |
| August 14, 2026 | 17.33M |
| August 13, 2026 | 16.47M |
| August 12, 2026 | 17.12M |
| August 11, 2026 | 17.55M |
| August 10, 2026 | 17.33M |
| August 07, 2026 | 17.12M |
| August 06, 2026 | 16.79M |
| August 05, 2026 | 16.47M |
| August 04, 2026 | 15.51M |
| August 03, 2026 | 15.94M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.925B |
| Corcept Therapeutics, Inc. | 12.78B |
| Veru, Inc. | 17.90M |
| Johnson & Johnson | 663.40B |
| Eli Lilly & Co. | 1.159T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.015M |
| Revenue (Quarterly) | 16.11M |
| Total Expenses (Quarterly) | 16.12M |
| EPS Diluted (Quarterly) | -0.0008 |
| Gross Profit Margin (Quarterly) | 59.90% |
| Profit Margin (Quarterly) | -0.09% |
| Earnings Yield | -83.36% |
| Normalized Earnings Yield | -83.36 |